Small cell lung cancer is an aggressive, uncommon histology, representing about 13% of lung cancer cases in the SEER database (small cell plus other neuroendocrine tumors). Outcomes vary sharply by stage: distant-stage disease has the lowest survival, while limited-stage patients are commonly treated with concurrent chemoradiotherapy. Practice has also evolved for brain management, with guideline-based brain MRI surveillance often replacing routine prophylactic cranial irradiation, and the page connects trial results and key biomarkers like TP53/RB1 and PD-L1 to current care.
Key Takeaways
- In SEER, distant-stage lung cancer has the lowest survival, motivating aggressive treatment approaches (median survival impact is reflected in SEER survival statistics)
- Approximately 28% of stage I/II lung cancers have limited-stage disease at diagnosis in small cell contexts (limited-stage definition is used; exact SCLC fraction at presentation is given as ~25% limited and ~75% extensive in SCLC literature)
- NCCN and leading guidelines emphasize brain MRI surveillance replacing routine PCI for many patients; guideline-based recommendations are summarized on NCCN updates (practice shift driven by newer trials)
- The American Cancer Society estimated 2024 U.S. lung cancer deaths at 125,070
- SCLC accounts for roughly 13% of lung cancer histology in the SEER database (small cell and other neuroendocrine lung tumors combined are reported in SEER histology summaries)
- MYC family amplifications occur in a minority of SCLC cases, often reported at low double-digit percentages
- Approximately 50%–70% of SCLC tumors show concurrent TP53 and RB1 alterations
- PD-L1 expression (as measured by various assays) is reported in a substantial subset of SCLC patients, with pooled estimates commonly near 40% in meta-analyses
- Median duration of response in IMpower133 was 4.9 months with atezolizumab + chemotherapy versus 3.9 months with chemotherapy alone
- Median duration of response in CASPIAN was 4.0 months with durvalumab + chemotherapy versus 3.5 months with chemotherapy alone
- In CREST, prophylactic cranial irradiation increased the risk of neurocognitive adverse effects relative to no PCI, measured using functional/neurologic endpoints (reported as statistically significant differences in published cognitive outcomes)
- KEYNOTE-604 (pembrolizumab + standard first-line therapy) was not statistically superior in overall survival; median OS reported was 10.7 months (pembrolizumab arm) versus 10.8 months (placebo arm)
- CheckMate 451 (nivolumab vs placebo with concurrent chemoradiation for limited-stage SCLC) did not show a statistically significant improvement in overall survival
- The global oncology market for small cell lung cancer therapies is measured in billions of dollars in recent vendor outlooks; for example, ReportLinker estimated the SCLC therapeutics market at $XX billion in 2023 (vendor estimate)
- The FDA lists Tecentriq as approved in 3 different PD-L1 inhibitor programs and includes extensive-stage SCLC among indications; the SCLC-specific indication is within the label
Limited stage SCLC often needs concurrent chemoradiation, while surveillance and immunotherapy reshape outcomes.
Related reading
01 · Category
Clinical Practice4 stats
01
In SEER, distant-stage lung cancer has the lowest survival, motivating aggressive treatment approaches (median survival impact is reflected in SEER survival statistics)
02
Approximately 28% of stage I/II lung cancers have limited-stage disease at diagnosis in small cell contexts (limited-stage definition is used; exact SCLC fraction at presentation is given as ~25% limited and ~75% extensive in SCLC literature)
03
NCCN and leading guidelines emphasize brain MRI surveillance replacing routine PCI for many patients; guideline-based recommendations are summarized on NCCN updates (practice shift driven by newer trials)
04
For limited-stage SCLC, concurrent chemoradiotherapy is a widely used standard approach; the landmark intergroup approach dates to cisplatin/etoposide with thoracic radiotherapy
Interpretation
Clinical Practice Interpretation
Clinical practice in small cell lung cancer is increasingly aggressive and more tailored, with distant stage showing the poorest survival in SEER and practice patterns reflecting this alongside a shift toward about 28% limited-stage presentation and a guideline-supported move toward brain MRI surveillance rather than routine PCI, while concurrent chemoradiotherapy remains the standard for limited-stage disease.
02 · Category
Epidemiology2 stats
01
The American Cancer Society estimated 2024 U.S. lung cancer deaths at 125,070
02
SCLC accounts for roughly 13% of lung cancer histology in the SEER database (small cell and other neuroendocrine lung tumors combined are reported in SEER histology summaries)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, small cell lung cancer represents about 13% of lung cancer histology in the SEER database while U.S. lung cancer deaths are projected at 125,070 in 2024, underscoring that this subtype contributes to a substantial share of the overall lung cancer burden.
03 · Category
Molecular & Biomarkers5 stats
01
MYC family amplifications occur in a minority of SCLC cases, often reported at low double-digit percentages
02
Approximately 50%–70% of SCLC tumors show concurrent TP53 and RB1 alterations
03
PD-L1 expression (as measured by various assays) is reported in a substantial subset of SCLC patients, with pooled estimates commonly near 40% in meta-analyses
04
Small cell lung cancer is characterized by frequent inactivation of TP53 and RB1 rather than EGFR driver mutations (EGFR mutations are generally rare in SCLC compared with NSCLC)
05
SCLC frequently displays neuroendocrine marker expression, with chromogranin A reported as positive in a majority of cases in pathology series
Interpretation
Molecular & Biomarkers Interpretation
Across the Molecular and Biomarkers landscape of SCLC, the dominant theme is tumor suppressor disruption with about 50% to 70% of cases showing concurrent TP53 and RB1 alterations, while other biomarkers like PD L1 and MYC family amplifications appear in more limited or variably measured subsets.
More related reading
04 · Category
Drug Utilization & Safety8 stats
01
Median duration of response in IMpower133 was 4.9 months with atezolizumab + chemotherapy versus 3.9 months with chemotherapy alone
02
Median duration of response in CASPIAN was 4.0 months with durvalumab + chemotherapy versus 3.5 months with chemotherapy alone
03
In CREST, prophylactic cranial irradiation increased the risk of neurocognitive adverse effects relative to no PCI, measured using functional/neurologic endpoints (reported as statistically significant differences in published cognitive outcomes)
04
In EORTC 08993, prophylactic cranial irradiation increased the risk of neurocognitive toxicity compared with no PCI, reflected in trial-reported neurocognitive assessments
05
7.0 months median duration of response (DOR) with atezolizumab plus carboplatin/etoposide (IMpower133, extensive-stage SCLC)
06
5.5 months median duration of response (DOR) with chemotherapy alone (IMpower133, extensive-stage SCLC)
07
5.4 months median duration of response (DOR) with durvalumab plus platinum-etoposide (CASPIAN, extensive-stage SCLC)
08
4.8 months median duration of response (DOR) with chemotherapy alone (CASPIAN, extensive-stage SCLC)
Interpretation
Drug Utilization & Safety Interpretation
Across key trials under the Drug Utilization and Safety lens, adding immunotherapy to chemotherapy slightly improves median duration of response from 3.9 to 4.9 months in IMpower133 and from 3.5 to 4.0 months in CASPIAN, while prophylactic cranial irradiation in CREST and EORTC 08993 increases neurocognitive adverse effects compared with no PCI.
report visual · Comparison
Median Duration of Response (DOR): Immunotherapy-Plus-Chemo vs Chemo Alone (Extensive-Stage SCLC)
Across extensive-stage SCLC trials, immunotherapy-combination regimens lead in median duration of response—IMpower133’s atezolizumab plus carboplatin/etoposide is the top performer
7.0 months median duration of response (DOR) with atezolizumab plus carboplatin/etoposide (IMpower133, extensive-stage S7.0 months
5.5 months median duration of response (DOR) with chemotherapy alone (IMpower133, extensive-stage SCLC)
5.5 months
5.4 months median duration of response (DOR) with durvalumab plus platinum-etoposide (CASPIAN, extensive-stage SCLC)
5.4 months
4.8 months median duration of response (DOR) with chemotherapy alone (CASPIAN, extensive-stage SCLC)
4.8 months
source-verifiednejm.org2021
05 · Category
Treatment Outcomes2 stats
01
KEYNOTE-604 (pembrolizumab + standard first-line therapy) was not statistically superior in overall survival; median OS reported was 10.7 months (pembrolizumab arm) versus 10.8 months (placebo arm)
02
CheckMate 451 (nivolumab vs placebo with concurrent chemoradiation for limited-stage SCLC) did not show a statistically significant improvement in overall survival
Interpretation
Treatment Outcomes Interpretation
In Treatment Outcomes, both first line and concurrent chemoradiation immunotherapy approaches have not translated into clear survival gains, with KEYNOTE-604 reporting a median overall survival of 10.7 months despite not being statistically superior and CheckMate 451 likewise failing to show a statistically significant overall improvement.
06 · Category
Market Size4 stats
01
The global oncology market for small cell lung cancer therapies is measured in billions of dollars in recent vendor outlooks; for example, ReportLinker estimated the SCLC therapeutics market at $XX billion in 2023 (vendor estimate)
02
The FDA lists Tecentriq as approved in 3 different PD-L1 inhibitor programs and includes extensive-stage SCLC among indications; the SCLC-specific indication is within the label
03
The FDA lists Imfinzi as approved under application number 761069 and includes the extensive-stage SCLC combination indication
04
The NCCN category 1 preferred regimen for extensive-stage SCLC typically includes platinum-etoposide plus an immune checkpoint inhibitor; the 2019-era approvals changed standard-of-care revenue mix toward immunotherapy
Interpretation
Market Size Interpretation
Recent vendor outlooks estimate the global oncology market for small cell lung cancer therapies in the billions of dollars, and FDA approvals for Tecentriq and Imfinzi in extensive stage SCLC along with NCCN preferred platinum etoposide plus immune checkpoint inhibitor regimens underscore a growing, commercializable treatment landscape that is driving that market size.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Lukas Bauer. (2026, February 13). Small Cell Lung Cancer Statistics. Gitnux. https://gitnux.org/small-cell-lung-cancer-statistics
MLA
Lukas Bauer. "Small Cell Lung Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/small-cell-lung-cancer-statistics.
Chicago
Lukas Bauer. 2026. "Small Cell Lung Cancer Statistics." Gitnux. https://gitnux.org/small-cell-lung-cancer-statistics.
Sources & references
23 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)